AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 252 min read$MLYS

Warren Eric sold $193K of MLYS

Warren Eric (Chief Commercial Officer) sold 7,437 shares of Mineralys Therapeutics, Inc. (MLYS) at $25.98 ($0.19M total) on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Warren Eric
Published Aug 25, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MLYS
Neutral
medium confidence
Mentioned
$MLYS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLYSNeutralLow
01

Why it matters

The disclosure updates the insider trading record for MLYS, but the text does not include any new business, financial, or regulatory development.

02

Market read

Primarily a sentiment datapoint for MLYS; actionable impact is likely limited absent additional catalysts.

03

What to watch

Traders may over-weight insider sales; without concurrent buys, guidance changes, or clinical/commercial milestones, the signal is typically weak.

Relevance 3/10Novelty 5/10Timing: Filed 2026-08-25 after-hours; trade occurred 2026-08-21.

Background

The article is an SEC Form 4 insider transaction disclosure for Mineralys Therapeutics, Inc.

Company-level read

Ticker impact

$MLYSNeutralMedium confidence
Context

Form 4 shows CCO Warren Eric sold 7,437 shares at $25.9767 on 2026-08-21 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; any move should be small unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine 10b5-1 sale disclosure with defined trade size and no accompanying operational or financial guidance changes in the text.

Market effects

Sector

No sector-wide read-through is provided; this is company-specific insider activity only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    Mineralys Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Warren Eric

    Chief Commercial Officer who sold shares.

  • trading_mechanism
    10b5-1 plan

    Pre-arranged plan cited as the basis for the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLYS insider trading history →

Related articles

AUG 22
$MLYSMed

Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Mineralys Therapeutics (MLYS) reported a Q2 2026 net loss of $241.07M. The company appointed James J. Ferguson III, M.D., as Chief Medical Officer. Shares are down 5.04% in 30 days and 14.07% in 90 days, but up 72.32% in 1 year and 97.31% in 3 years. Analysts suggest fair value at $50.88, above the current $25.65, based on lorundrostat's potential. Risks include regulatory outcomes and cash burn.

simplywall.st2 min
AUG 19
$MLYSMed

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics (MLYS) reported Q2 2026 earnings, highlighting a net loss of $241.1 million due to royalty repurchase obligations. Key financial activities included a $150 million equity offering and a $100 million tranche from a $500 million loan. The company is preparing for the FDA's PDUFA date for lorundrostat, a hypertension treatment, with commercial launch plans and payer discussions underway. Management expressed optimism about the regulatory review and market potential.

fool.com4 min
AUG 13
$MLYSMed

Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary

Mineralys Therapeutics reported Q2 2026 updates on lorundrostat. The company said it repurchased future royalties from Mitsubishi Tanabe for $200 million, secured a $500 million senior secured term loan, and completed a $150 million equity offering. R&D rose to $221.4 million. It cited LAUNCH-HTN results and targeted a Dec. 22, 2026 PDUFA, with FDA discussions in Oct-Nov 2026.

yahoo.com7 min
AUG 11
$MLYSMed

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics (MLYS) discussed exploratory proteomic biomarker results from its Launch-HTN and Advance-HTN trials at ENDO 2026, with management saying lorundrostat was linked to reductions in heart-failure risk biomarkers. The company expects FDA discussions to intensify near the October-November PDUFA window, and outlined U.S. payer and physician outreach ahead of a December PDUFA launch. Q2 cash was $661.4M; net loss was $241.1M.

yahoo.com6 min
AUG 11
$MLYSMedAI 8/10

Why is Mineralys Therapeutics stock sliding today?

Investing.com reports Mineralys Therapeutics (MLYS) shares fell 4.9% in after-hours after posting a Q2 2026 per-share loss of $2.85 versus a $2.63 analyst consensus. The loss followed a rise in operating costs, including $221.4 million R&D and a $200 million upfront payment to Tanabe for lorundrostat royalty buyout. FDA PDUFA is Dec. 22, 2026.

investing.com4 min
AUG 11
$MLYSMed

Mineralys Therapeutics, Inc. (MLYS): Results of Operations and Financial Condition

Mineralys Therapeutics, Inc. (MLYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update – PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine e

SEC EDGAR 8-K6 min